Under 10% of patients that would benefit from obesity jabs such as Wegovy can access them, warns the World Health Organization as it releases its inaugural recommendations on the drugs.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for more widespread and fairer availability to these injectable treatments.
Per forecasts, more than two billion are projected to be obese by 2030 unless action is taken.
"Our latest guidelines recognises that excess weight is a chronic disease that can be treated with comprehensive and continuous care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major obstacles to universal access to the jabs that can aid individuals in losing significant weight, notes the agency.
Skinny Jab Supply Crisis
Despite the present most optimistic outlook, the production of GLP-1 therapies might only reach about 100 million people – fewer than 10% of eligible patients, per the health organization.
The recommendation calls on countries and companies to increase access, by measures such as licensing agreements.
The intellectual property rights on a key compound – the primary component of the drug Wegovy – is scheduled to end in a number of countries in 2026.
How Weight-Loss Injections Function
GLP-1 drugs replicate a biological compound to reduce digestion speed, suppress the appetite and enhance the sense of being full so users reduce food intake.
Patients usually see weight reduction in the initial weeks of starting on the regular doses.
Evidence points to users may see weight return within a year of stopping the drug, when their usual appetite come back.
Being overweight or obese raises your risk for developing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity affects people in every country and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.
